Patients’ and Caregivers’ Preferences for Bone Metastases (BM) Treatments in the United States

Abstract

tiveness analyses were compared with methods specified by NICE as the reference case in its 2004 and 2008 Methods Guides. The review focused on guidance published before June 2013 for medicines treating metastatic breast cancer, metastatic colorectal cancer, metastatic hormone-refractory prostate cancer and metastatic non-smallcell lung cancer. Nineteen technology appraisals published between March 2002 and August 2012 met the inclusion criteria. Results: Common themes or variations that exist between utility values selected by manufacturers and independent academic groups for each metastatic cancer and between the 4 metastatic cancers were analysed. The research also explored the methodological issues that were considered by the Appraisal Committee relating to the selection of utility values. ConClusions: Therefore, this research provides insight to the methodological considerations regarding incorporation of utility values that have informed health technology assessment decision-making in England for 4 metastatic cancers.

Patients’ and Physicians’ Preferences for Approaches to Bone Metastases Treatment in Turkey

“…14,15 In a study of physicians, patients, caregivers, and nurses in the USA, out-of-pocket cost to patients, time to first SRE, and risk of renal impairment were rated as the most important BTA attributes by each group. [30][31][32] These studies confirm that treatments that delay SREs and worsening of pain with a low risk of renal impairment are desirable in the opinions of both patients and physicians across Europe and the USA.…”

Physicians’ Preferences for Bone Metastases Drug Therapy in the United States

“…as the most important attributes when choosing pharmacologic therapy for the prevention of SREs in patients with bone metastases due to solid tumors. Given that out-of-pocket costs are the most important attribute in this analysis, it seems that physicians understand that such costs, which vary in the United States by health plan and coverage, are an important factor for patients, and indeed, studies have confirmed that this is of relatively equal importance for both physicians and patients [27]. These observations underscore the importance of increasing awareness of health plan coverage and patient support programs to enable caregivers to present a more comprehensive view of available treatment options for bone metastases, facilitating a joint treatment decision between physicians and patients.…”

Treatment Patterns of Bone-targeting Agents Among Solid Tumor Patients With Bone Metastases

“…24,25 Given the wide variation in adherence to recommended treatment guidelines due to patient or provider preference, patient comorbidities, or contraindications, assessment of real-world BTA treatment patterns in patients with BM is essential. [26][27][28] Previous realworld studies of BTA treatment patterns in the US have reported that 47.0% of Medicare and 43.2% of commercially insured patients with BM across cancer types were administered BTAs. 24 The proportion of BTA-treated patients with breast cancer in the US was 66.6% to 69.0%, 24,29 which is lower than that for Europe, where 88% of patients with breast cancer received BTAs after BM diagnoses; 28 delays in BTA administration were often associated with the physician's decision.…”

“…Examination of real-world BTA treatment patterns in patients with BM in the US is limited 24,25 . Given the wide variation in adherence to recommended treatment guidelines due to patient or provider preference, patient comorbidities, or contraindications, assessment of real-world BTA treatment patterns in patients with BM is essential 26–28 . Previous real-world studies of BTA treatment patterns in the US have reported that 47.0% of Medicare and 43.2% of commercially insured patients with BM across cancer types were administered BTAs 24 .…”